EUVIMEDEUVIMED entdecken
Crossref

Residual plasma Epstein–Barr virus DNA after intensity-modulated radiation therapy is associated with poor outcomes in nasopharyngeal carcinoma

Ping Zhou, Juan Zhou iD, Chen-Lu Lian, Yi-Feng Yu, Rui Zhou, Qin Lin, San-Gang Wu iD

Future Oncology · 2023-10 · 19 (33) · 2227-2235

DOI: 10.2217/fon-2023-0818 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2023-11. Verfasst von Ping Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: The School of Clinical Medicine, Fujian Medical University, Fuzhou, 350122, China. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Carcinoma, Nasopharyngeal Neoplasms, Radiotherapy, Intensity-Modulated. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the effects of residual plasma Epstein-Barr virus (EBV) DNA levels after 3 months of intensity-modulated radiation therapy (IMRT) (postIMRT-EBV DNA) on prognosis in patients with nasopharyngeal carcinoma.

Methods

Data from 300 patients were retrospectively collected for analysis.

Results

Of these patients, 25 (8.3%) and 275 (91.7%) had positive and negative postIMRT-EBV DNA, respectively. Multivariate survival analysis showed that EBV DNA >688 IU/ml was independently associated with inferior distant metastasis-free survival (p = 0.003) and progression-free survival (p = 0.002). Moreover, postIMRT-EBV DNA was independently associated with inferior locoregional recurrence-free survival (hazard ratio: 4.325; p = 0.018), distant metastasis-free survival (hazard ratio: 10.226; p < 0.001) and progression-free survival (hazard ratio: 10.520; p < 0.001).

Conclusion

Positive postIMRT-EBV DNA is a prognostic biomarker for nasopharyngeal carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsCarcinomaNasopharyngeal NeoplasmsRadiotherapy, Intensity-ModulatedHumansNasopharyngeal CarcinomaHerpesvirus 4, HumanRetrospective StudiesDNA, ViralPrognosis

Stichwörter der Autor:innen

EBV DNAIMRTbiomarkernasopharyngeal carcinomaprognosisradiotherapysurvival

Substanzen

DNA, Viral

Autor:innen und Institutionen

  • The School of Clinical Medicine, Fujian Medical University, Fuzhou, 350122, China.
  • Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China.
  • Department of Radiation Oncology, Fudan University Shanghai Cancer Center (Xiamen Branch), Xiamen, 361027, China.
  • Department of Obstetrics & Gynecology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China.

ORCID-Profile: Juan Zhou, San-Gang Wu

Zitieren

APA

Zhou, P., Zhou, J., Lian, C. L., Yu, Y. F., Zhou, R., Lin, Q., & Wu, S. G. (2023). Residual plasma Epstein–Barr virus DNA after intensity-modulated radiation therapy is associated with poor outcomes in nasopharyngeal carcinoma. Future Oncology, 19(33), 2227-2235. https://doi.org/10.2217/fon-2023-0818

Vancouver

Zhou P, Zhou J, Lian CL, Yu YF, Zhou R, Lin Q, et al. Residual plasma Epstein–Barr virus DNA after intensity-modulated radiation therapy is associated with poor outcomes in nasopharyngeal carcinoma. Future Oncology. 2023;19(33):2227-2235. doi:10.2217/fon-2023-0818

BibTeX
@article{Zhou2023,
  author = {Zhou, Ping and Zhou, Juan and Lian, Chen-Lu and Yu, Yi-Feng and Zhou, Rui and Lin, Qin and Wu, San-Gang},
  title = {Residual plasma Epstein–Barr virus DNA after intensity-modulated radiation therapy is associated with poor outcomes in nasopharyngeal carcinoma},
  journal = {Future Oncology},
  year = {2023},
  volume = {19},
  number = {33},
  pages = {2227--2235},
  doi = {10.2217/fon-2023-0818}
}
Kostenlos starten →